Relesium combines chicken egg powder and bovine colostrum, offering an all-natural solution for companies that want to address digestive issues, such as nausea, acid reflux, bloating, constipation and diarrhea that many people experience while taking GLP-1 (glucagon-like peptide 1) medications.
“Relesium is entering a largely untapped market addressing a need for an all-natural, fast-acting and patented solution to alleviate the GI discomfort millions worldwide experience,” said Tom Feeley, CEO of PanTheryx.
He added that Relesium helps restore the gut microbiome.
“This ingredient now allows health and wellness companies to offer their customers a science-backed product that addresses these [side effects] without compromising the effectiveness of their GLP-1 therapy and additional medications.”
According to PanTheryx, one in eight Americans now rely on GLP-1 drugs for weight loss, diabetes and other health conditions, and nearly 50% of GLP-1 patients report mild to moderate gastrointestinal side effects.
This can lead to people taking reduced dosages of the drugs, and close to 30% of users discontinue treatment. Recommendations suggest users should modify their diets to consume smaller, more bland meals, though many are turning to additional means of support while taking GLP-1 medications.
Research findings
Researchers at the University of West London published a review in Nutrients on the synergistic potential of Relesium, highlighting egg and bovine colostrum (BC) as "rich sources of macro- and micro-nutrients and bioactive molecules that have potential relevance for immunity, growth and repair."
They noted that egg and BC are considered ‘superfoods’ and that strong in vitro and in vivo peer-reviewed studies suggest the potential benefits, including addressing gastrointestinal conditions. However, more translational studies are needed to establish egg and BC use in clinical practice, the researchers wrote.
Adding to this body of research, PanTheryx commissioned an observational pilot study to explore Relesium’s effectiveness among GLP-1 medication patients.
Eighteen participants using GLP-1 medications enrolled in the study. Ten of them experienced gastrointestinal symptoms and were administered Relesium. Initial results show that all 10 reported improvement and reduction in gut-related symptoms after adding Relesium to their regimen. A placebo-controlled trial is planned to further confirm efficacy.
The observational study was led by Dr. Harry Oken, M.D., an internist and adjunct professor of medicine at the University of Maryland, and Dr. Michael Roizen, M.D., an internist, anesthesiologist and chief wellness officer emeritus at the Cleveland Clinic.
“The rapid improvements observed with Relesium offer a natural remedy and show strong potential to help patients feel better, faster,” said Dr. Oken. “By easing gastrointestinal distress and aiding gut health, Relesium enables patients to comfortably and safely take the prescribed dose of GLP-1s in order to achieve their maximum intended benefits.”